- Home
- EIC vs PRTA Comparison
EIC vs PRTA Comparison
Compare EIC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- PRTA
- Stock Information
- Founded
- EIC N/A
- PRTA 2012
- Country
- EIC United States
- PRTA Ireland
- Employees
- EIC N/A
- PRTA N/A
- Industry
- EIC Finance/Investors Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- PRTA Health Care
- Exchange
- EIC Nasdaq
- PRTA Nasdaq
- Market Cap
- EIC 343.8M
- PRTA 366.6M
- IPO Year
- EIC 2019
- PRTA N/A
- Fundamental
- Price
- EIC $13.38
- PRTA $8.77
- Analyst Decision
- EIC Strong Buy
- PRTA Buy
- Analyst Count
- EIC 1
- PRTA 10
- Target Price
- EIC $17.50
- PRTA $24.29
- AVG Volume (30 Days)
- EIC 253.1K
- PRTA 1.1M
- Earning Date
- EIC 08-12-2025
- PRTA 08-04-2025
- Dividend Yield
- EIC 11.70%
- PRTA N/A
- EPS Growth
- EIC N/A
- PRTA N/A
- EPS
- EIC 0.70
- PRTA N/A
- Revenue
- EIC $55,581,156.00
- PRTA $10,341,000.00
- Revenue This Year
- EIC $37.84
- PRTA N/A
- Revenue Next Year
- EIC $23.33
- PRTA $122.46
- P/E Ratio
- EIC $19.15
- PRTA N/A
- Revenue Growth
- EIC 56.39
- PRTA N/A
- 52 Week Low
- EIC $12.10
- PRTA $4.32
- 52 Week High
- EIC $16.71
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- EIC 60.36
- PRTA 80.26
- Support Level
- EIC $12.10
- PRTA $8.28
- Resistance Level
- EIC $13.15
- PRTA $8.70
- Average True Range (ATR)
- EIC 0.21
- PRTA 0.44
- MACD
- EIC 0.11
- PRTA 0.08
- Stochastic Oscillator
- EIC 99.15
- PRTA 91.07
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.